Pfenex Inc (NYSEMKT:PFNX) will announce its earnings results after the market closes on Thursday, November 9th. Analysts expect the company to announce earnings of ($0.56) per share for the quarter.

Pfenex (NYSEMKT:PFNX) last posted its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.46) by ($0.06). Pfenex had a negative return on equity of 75.61% and a negative net margin of 406.87%. The firm had revenue of $3.03 million for the quarter, compared to analyst estimates of $3.10 million. During the same quarter last year, the firm earned ($0.43) EPS. The company’s revenue was down 3.5% on a year-over-year basis.

Pfenex Inc (NYSEMKT PFNX) opened at $3.14 on Tuesday. Pfenex Inc has a twelve month low of $2.54 and a twelve month high of $11.35.

ILLEGAL ACTIVITY WARNING: “Pfenex Inc (PFNX) Set to Announce Quarterly Earnings on Thursday” was originally published by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another site, it was illegally stolen and republished in violation of United States and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.watchlistnews.com/pfenex-inc-pfnx-set-to-announce-quarterly-earnings-on-thursday/1684106.html.

A number of brokerages recently commented on PFNX. Zacks Investment Research raised shares of Pfenex from a “hold” rating to a “buy” rating and set a $3.00 price target for the company in a report on Tuesday, October 24th. William Blair reaffirmed an “ourperform” rating on shares of Pfenex in a report on Friday, September 8th. Finally, ValuEngine downgraded shares of Pfenex from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st.

About Pfenex

Pfenex Inc is a clinical-stage biotechnology company. The Company is engaged in the development of biosimilar and therapeutic equivalent products to branded therapeutics and other high-value and difficult-to-manufacture proteins. Its lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab).

Earnings History for Pfenex (NYSEMKT:PFNX)

Receive News & Ratings for Pfenex Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfenex Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.